Rapport Therapeutics, a neuroscience technology company from Johnson & Johnson, went public and raised $154 million for proof-of-concept testing of a lead program for epilepsy. The company’s IPO raised $136 million, with an additional $18 million in a private placement. Their lead drug candidate RAP-219 targets AMPA receptors for focal epilepsy treatment, aiming to reduce side effects. The technology was licensed from Janssen, a Johnson & Johnson subsidiary. Rapport plans to start a mid-stage clinical trial for RAP-219 and allocate funding for further development. The company aims to use the raised capital to advance their drug candidates and expand their pipeline.
Source link
Rapport’s Stock Market Debut Reaps $154M as Novel Epilepsy Med Heads for Mid-Stage Test
